Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	654,937	385,113	457,800	533,530	849,695	273,966
Short-Term Investments	107,004	20,476	15,089	20,174	25,305	536,260
Cash & Short-Term Investments	761,941	405,589	472,889	553,704	875,000	810,226
Cash Growth	44.65%	-14.23%	-14.59%	-36.72%	7.99%	24.00%
Accounts Receivable	736,464	709,465	668,403	649,429	696,644	125,748
Other Receivables	21,457	15,789	29,207	32,264	27,733	46,114
Total Trade Receivables	757,921	725,254	697,610	681,693	724,377	171,862
Inventory	1,407,190	1,217,350	1,209,870	986,457	853,167	90,702
Other Current Assets	189,387	173,000	178,212	176,103	141,099	126,099
Total Current Assets	3,116,440	2,521,190	2,558,580	2,397,960	2,593,640	1,198,890
Net Property, Plant & Equipment	2,083,980	1,968,210	1,989,780	1,691,230	1,582,800	140,114
Other Intangible Assets	3,515,630	3,631,560	4,274,680	4,269,660	3,818,540	19,586
Goodwill	5,753,270	5,324,430	5,410,070	4,790,720	4,407,750	-
Long-Term Investments	434,168	361,926	430,608	378,857	330,133	9,258,340
Other Long-Term Assets	505,288	441,027	445,079	429,328	445,150	239,524
Total Assets	15,408,800	14,248,300	15,108,800	13,957,800	13,178,000	10,856,500
Accounts Payable	467,594	475,541	547,521	649,233	516,297	-
Current Portion of Long-Term Debt	583,147	548,939	367,251	339,600	203,993	-
Other Current Liabilities	1,559,440	1,482,040	1,398,330	1,493,110	1,425,440	-
Total Current Liabilities	2,610,180	2,506,520	2,313,100	2,481,940	2,145,730	1,832,360
Long-Term Debt	4,270,170	3,966,330	4,476,500	4,042,740	4,141,420	-
Other Long-Term Liabilities	884,326	839,518	1,045,180	1,078,400	1,207,350	-
Total Long-Term Liabilities	5,154,500	4,805,840	5,521,680	5,121,140	5,348,760	4,589,200
Total Liabilities	7,764,680	7,312,370	7,834,790	7,603,080	7,494,500	6,421,560
Common Stock	1,694,760	1,694,690	1,676,600	1,676,350	1,676,260	1,668,150
Treasury Stock	-49,124	-74,815	-51,259	-100,317	-116,007	-59,523
Additional Paid-in Capital	1,751,910	1,775,710	1,747,410	1,728,830	1,708,870	1,257
Accumulated Other Comprehensive Income	3,149,740	2,351,920	2,509,310	1,508,120	934,173	-39,229
Retained Earnings	1,095,660	1,187,590	1,391,200	1,541,150	1,479,720	1,175,720
Total Common Shareholders' Equity	7,642,940	6,935,080	7,273,260	6,354,120	5,683,020	2,746,370
Minority Interest	1,147	895	741	549	504	-
Shareholders' Equity	7,644,090	6,935,980	7,274,010	6,354,670	5,683,520	4,434,890
Total Liabilities & Equity	15,408,800	14,248,300	15,108,800	13,957,800	13,178,000	10,856,500
Total Debt	4,853,320	4,515,270	4,843,750	4,382,340	4,345,410	0
Net Cash (Debt)	-4,091,380	-4,109,680	-4,370,860	-3,828,640	-3,470,410	810,226
Net Cash Per Share	-1288.04	-1280.02	-1382.88	-1219.41	-1100.20	257.45
Book Value	7,642,940	6,935,080	7,273,260	6,354,120	5,683,020	2,746,370
Book Value Per Share	2406.14	2160.03	2301.17	2023.77	1801.65	872.67
Tangible Book Value	-1,625,950	-2,020,910	-2,411,490	-2,706,260	-2,543,270	2,726,780
Tangible Book Value Per Share	-511.88	-629.44	-762.96	-861.94	-806.28	866.45

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q